Inhibit the JAK pathway and help control disease in patients with:
Polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea1
Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post–polycythemia
vera myelofibrosis and post–essential thrombocythemia myelofibrosis.1
IncyteCARES may be able to help with Co-pay Assistance for Jakafi® (ruxolitinib) for your patients.
- Jakafi Prescribing Information. Incyte Corporation.
What would you like to do?